BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 25287587)

  • 1. Human immunodeficiency virus vaccines.
    Goepfert P; Bansal A
    Infect Dis Clin North Am; 2014 Dec; 28(4):615-31. PubMed ID: 25287587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Policy rebuttal. HIV vaccine trial justified.
    McNeil JG; Johnston MI; Birx DL; Tramont EC
    Science; 2004 Feb; 303(5660):961. PubMed ID: 14963313
    [No Abstract]   [Full Text] [Related]  

  • 3. Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans.
    Pissani F; Schulte B; Eller MA; Schultz BT; Ratto-Kim S; Marovich M; Thongcharoen P; Sriplienchan S; Rerks-Ngarm S; Pitisuttithum P; Esser S; Alter G; Robb ML; Kim JH; Michael NL; Streeck H
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30209165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge.
    Styles TM; Gangadhara S; Reddy PBJ; Hicks S; LaBranche CC; Montefiori DC; Derdeyn CA; Kozlowski PA; Velu V; Amara RR
    J Virol; 2019 Oct; 93(20):. PubMed ID: 31341049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
    GarcĂ­a-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2017 May; 91(9):. PubMed ID: 28179536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a DNA-MVA/HIVA vaccine for Kenya.
    Hanke T; McMichael AJ; Mwau M; Wee EG; Ceberej I; Patel S; Sutton J; Tomlinson M; Samuel RV
    Vaccine; 2002 May; 20(15):1995-8. PubMed ID: 11983261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group.
    Corey L; McElrath MJ; Weinhold K; Matthews T; Stablein D; Graham B; Keefer M; Schwartz D; Gorse G
    J Infect Dis; 1998 Feb; 177(2):301-9. PubMed ID: 9466515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV vaccines: can CD4+ T cells be of help?
    Van Braeckel E; Leroux-Roels G
    Hum Vaccin Immunother; 2012 Dec; 8(12):1795-8. PubMed ID: 22906935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV vaccines: progress to date.
    Munier CM; Andersen CR; Kelleher AD
    Drugs; 2011 Mar; 71(4):387-414. PubMed ID: 21395355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
    Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
    J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses.
    Zurawski G; Shen X; Zurawski S; Tomaras GD; Montefiori DC; Roederer M; Ferrari G; Lacabaratz C; Klucar P; Wang Z; Foulds KE; Kao SF; Yu X; Sato A; Yates NL; LaBranche C; Stanfield-Oakley S; Kibler K; Jacobs B; Salazar A; Self S; Fulp W; Gottardo R; Galmin L; Weiss D; Cristillo A; Pantaleo G; Levy Y
    J Virol; 2017 May; 91(9):. PubMed ID: 28202751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV/AIDS vaccines: 2007.
    Robinson HL
    Clin Pharmacol Ther; 2007 Dec; 82(6):686-93. PubMed ID: 17971817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a Live Recombinant BCG Expressing Human Immunodeficiency Virus Type 1 (HIV-1) Gag Using a pMyong2 Vector System: Potential Use As a Novel HIV-1 Vaccine.
    Kim BJ; Kim BR; Kook YH; Kim BJ
    Front Immunol; 2018; 9():643. PubMed ID: 29636755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles.
    Bridge SH; Sharpe SA; Dennis MJ; Dowall SD; Getty B; Anson DS; Skinner MA; Stewart JP; Blanchard TJ
    Virol J; 2011 Sep; 8():429. PubMed ID: 21899739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The design and evaluation of HIV-1 vaccines.
    Saunders KO; Rudicell RS; Nabel GJ
    AIDS; 2012 Jun; 26(10):1293-302. PubMed ID: 22706011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virus-like vaccines against HIV/SIV synergize with a subdominant antigen T cell vaccine.
    Schwerdtfeger M; Andersson AC; Neukirch L; Holst PJ
    J Transl Med; 2019 May; 17(1):175. PubMed ID: 31126293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
    Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
    J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV Vaccine: Recent Advances, Current Roadblocks, and Future Directions.
    Rubens M; Ramamoorthy V; Saxena A; Shehadeh N; Appunni S
    J Immunol Res; 2015; 2015():560347. PubMed ID: 26579546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines.
    Amara RR; Villinger F; Staprans SI; Altman JD; Montefiori DC; Kozyr NL; Xu Y; Wyatt LS; Earl PL; Herndon JG; McClure HM; Moss B; Robinson HL
    J Virol; 2002 Aug; 76(15):7625-31. PubMed ID: 12097576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tiny steps towards an HIV vaccine.
    Willyard C
    Nature; 2010 Jul; 466(7304):S8. PubMed ID: 20631706
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.